Monogram Biosciences' PhenoSense™ HIV Neutralization, or "Neutralizing
Antibody" assay, is available to pharmaceutical and vaccine companies and
researchers involved in HIV vaccine, therapeutic antibody research and studies
of natural history of infection with HIV. The assay is offered in 3 different
formats: HITS, CURVES and CURVES PLUS. HITS is a 4 dilution format used for
screening large numbers of plasmas, CURVES format includes a 10 dilution curve
that generates IC50s, IC80s, IC90s and IC95s, and the CURVES PLUS offering is
the 10 dilution CURVES format plus the percent inhibition of virus at each
dilution.
Monogram maintains a large library (virus pools and clones) of HIV-1 envelopes
(gp160), including numerous non-subtype B viruses, which allow for virus panel
customization. This library includes commonly available lab strain and
repository viruses as well as thousands of primary patient isolates. Clients
may also send their own viruses (e.g., a vaccine strain) for testing. Monogram
Biosciences has recently developed a panel of 20 subtype B viruses from
acute/early infection. The antibody neutralization sensitivity, tropism and
gp160 sequences have been determined for all isolates. This panel represents
currently circulating U.S. viruses and is a Tier 2 Panel for evaluation of sera
from candidate vaccines.
Monogram is also very active in studying the co-evolution of HIV envelope and
the antibody response at various stages of infection. Monogram's ability to
clone virus envelope directly from any virus source, particularly patient
plasma/serum samples allows study of the evolving virus and antibody response
in HIV infected patients without the artificial selection inherent in culturing
virus or selecting individual clones.
Click here to
download the Neutralization Brochure.
Related Literature:
Richman DD, Wrin T, Little SJ, Petropoulos CJ.
Rapid evolution of the neutralizing antibody response to HIV type 1 infection.
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9. Epub 2003 Mar 18
Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G,
Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR.
Comprehensive cross-clade neutralization analysis of a panel of anti-human
immunodeficiency virus type 1 monoclonal antibodies.
J Virol. 2004 Dec;78(23):13232-52
Deeks SG, Schweighardt B, Wrin T, Galovich J, Hoh R, Sinclair E, Hunt
P, McCune JM, Martin JN, Petropoulos CJ, Hecht FM.
Neutralizing antibody responses against autologous and heterologous viruses in
acute versus chronic human immunodeficiency virus (HIV) infection: evidence for
a constraint on the ability of HIV to completely evade neutralizing antibody
responses.
J Virol. 2006 Jun;80(12):6155-64.
Frost, S. D., Wrin, t., Smith, D. M., Kosakovsky Pond, S. L., Liu, Y., Paxinos,
E., Chappey, C., Galovich, J., Beauchaine, J., Petropoulos, C. J., Little, S.
J. & Richman, D. D.
Neutralizing Antibody Responses Drive the Evolution of Human Immunodeficiency
Virus Type 1 Envelope During Recent HIV Infection.
Proc Natl Acad Sci U S A 102, 18514-9 (2005).
For more information on Monogram assays, services and pricing, please contact us.
